Samsung Biologics announces all-cash offer to acquire PolyPeptide, accelerating multi-modality strategy and expanding global network across U.S., Europe, and India

Samsung Biologics has announced an all-cash public tender offer to acquire 100% of PolyPeptide Group AG's fully diluted share capital at a price of CHF 44.31 per share, valuing the transaction at approximately CHF 1.46 billion. The offer, which was made public on July 19, 2026, has received unanimous support from PolyPeptide's Board of Directors, who have recommended that shareholders accept the offer. The transaction is expected to close towards the end of 2026, pending regulatory approvals and other customary conditions.

PolyPeptide Group AG, based in Switzerland, is a prominent contract development and manufacturing organization (CDMO) specializing in peptide-based active pharmaceutical ingredients (APIs). With over 70 years of experience, PolyPeptide has established itself as a leader in the peptide CDMO sector, having produced more than 1,000 therapeutic peptides. The company operates a global network of facilities across Sweden, Belgium, France, the United States, and India, providing it with a robust integrated development-to-commercial model that allows for rapid adaptation to market demands.

The strategic rationale behind Samsung Biologics' acquisition lies in the growing demand for peptide therapeutics, particularly in the treatment of obesity and diabetes, where peptide-based therapies such as GLP-1 are gaining traction. By acquiring PolyPeptide, Samsung Biologics aims to enhance its multi-modality capabilities and expand its global manufacturing footprint. This acquisition will not only add significant capacity but also integrate PolyPeptide's specialized expertise into Samsung's existing operations, thereby creating a differentiated end-to-end CDMO platform.

The transaction is indicative of broader trends within the biopharmaceutical industry, where there is an increasing focus on peptide therapeutics as a viable treatment option across various disease areas. The combination of Samsung Biologics' extensive manufacturing scale and PolyPeptide's advanced technological capabilities positions the merged entity to capitalize on emerging opportunities in high-growth segments such as oncology and other therapeutic indications.

As the market for peptide-based therapies continues to expand, the acquisition of PolyPeptide by Samsung Biologics is expected to strengthen the latter's competitive position and enhance its service offerings. This move reflects a strategic commitment to long-term growth through diversification and innovation, aligning with the evolving needs of clients in the biopharmaceutical sector. The successful integration of PolyPeptide's operations and expertise will be crucial for Samsung Biologics as it seeks to solidify its status as a leading global multi-modality CDMO.